Stock market

[Guest guest]

I'm curious to know if the stock market reacted this at all. I'm

hoping that the stocks of pharm companies plummeted.

That's we they need to be hit.

[Guest guest]

Speaking of stocks. This company seems interesting, in light of the vaccine preservative controversy.CARRINGTON SUBSIDIARY DELSITE PREDICTSPRESERVATIVE-FREE VACCINES IN WORLD'S FUTURE• Preservative-free• Nasal Administration• No Cold Storage Required• Dry Powder SystemIRVING, TEXAS June 25, 2007 Vaccines are one of the earliest "wonder drugs" having saved millions of lives since their inception, and virtually wiped out killer diseases like smallpox, diphtheria and whooping cough in the developed world. Despite their great success, questions have been raised about possible adverse reactions, relating either to the vaccine or to the preservatives many vaccines contain to prevent bacterial and fungal contamination.In view of the current public concerns over vaccine preservatives, Carrington Laboratories, Inc. (Nasdaq: CARN) wants to update the progress that its wholly-owned subsidiary, DelSite Biotechnologies, Inc., continues to make in developing its novel drug delivery technology that aims to eliminate the need for preservatives in vaccines in the future.Preservatives are currently required in the U.S. for all biologic vaccines to prevent bacterial and fungal contamination of the product. Carrington believes this could change if DelSite is successful in its quest to commercialize its proprietary GelVac™ and GelSite® vaccine and drug delivery systems which could revolutionize how vaccines are stabilized, transported, stored and delivered to the body without risk of contamination.GelVac™ is a dry powder delivery system containing the unique, organically derived GelSite® polymer that gels in situ, that is, when it comes into contact with body fluids. The system requires no organic solvent in the manufacturing process, uses no preservatives, and does not require refrigeration. As a nasal delivery system, because it gels in situ, the polymer is mucoadhesive and thus provides prolonged nasal residence time, which optimizes antigen delivery. Both systemic and mucosal immunity are induced with nasal immunization. Further, the system offers room temperature stability, prolonged shelf life, distribution without refrigeration, and needle-free administration.stock symbol: CARN.OB>> I'm curious to know if the stock market reacted this at all. I'm> hoping that the stocks of pharm companies plummeted.> > That's we they need to be hit.> > >